NEXT Oncology – Madrid enrolled its first patient in March 2022 in an early phase clinical trial focused on metastatic triple negative breast cancer with an anti-drug conjugate used in monotherapy or in combination with antiPDL1. NEXT Oncology expanded to Spain in late 2021.
A study led by MedUni Vienna showed that, due to the omicron variant of COVID-19, there is an increasing number of breakthrough infections in people with cancer, especially those undergoing cancer therapy.
Acute lymphoblastic leukemia cells from patients whose cancers did not respond to CD19-targeted CAR T-cell therapy had gene regulation signatures that could potentially facilitate treatment resistance, according to results presented at the 2022 AACR annual meeting, April 8-13.
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer, researchers from The University of Texas MD Anderson Cancer Center reported at the 2022 AACR annual meeting.
Researchers at The University of Texas MD Anderson Cancer Center have developed a bioinformatics platform that predicts optimal treatment combinations for a given group of patients based on co-occurring tumor alterations. In retrospective validation studies, the tool selected combinations that resulted in improved patient outcomes across both pre-clinical and clinical studies.
Combining a retrospective analysis of clinical records with in-depth laboratory studies, researchers at The University of Texas MD Anderson Cancer Center have discovered that vitamin E can enhance immunotherapy responses by stimulating the activity of dendritic cells in the tumor.
Susana Garcia-Recio, a research associate in the lab of Charles M. Perou at the UNC Lineberger Comprehensive Cancer Center, presented findings at the 2022 AACR annual meeting that identified molecular features responsible for the development and progression of metastatic breast cancer.
Following an analysis of over 12,000 human genes, research from Yale Cancer Center indicated there is cancer-relevant importance in a much larger proportion of human genes than current cancer research models suggest.
Data generated using the Duomic platform, sponsored by IsoPlexis Corporation, demonstrated the ability to connect T-cell receptor diversity to the most functionally potent single cells, according to findings presented at the 2022 AACR annual meeting.
African-American adult patients are more likely than white patients to receive substandard gastrointestinal cancer surgery, according to a large study led by researchers at Yale Cancer Center.
